Beta Bionics Statistics
Total Valuation
Beta Bionics has a market cap or net worth of $737.83 million. The enterprise value is $563.85 million.
| Market Cap | 737.83M |
| Enterprise Value | 563.85M |
Important Dates
The last earnings date was Wednesday, July 29, 2026, after market close.
| Earnings Date | Jul 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Beta Bionics has 44.99 million shares outstanding. The number of shares has increased by 102.32% in one year.
| Current Share Class | 44.99M |
| Shares Outstanding | 44.99M |
| Shares Change (YoY) | +102.32% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 5.40% |
| Owned by Institutions (%) | 78.94% |
| Float | 19.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.20 |
| Forward PS | 4.77 |
| PB Ratio | 2.88 |
| P/TBV Ratio | 2.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.88, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.88 |
| Quick Ratio | 7.72 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.16% and return on invested capital (ROIC) is -18.17%.
| Return on Equity (ROE) | -26.16% |
| Return on Assets (ROA) | -16.67% |
| Return on Invested Capital (ROIC) | -18.17% |
| Return on Capital Employed (ROCE) | -31.17% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $281,355 |
| Profits Per Employee | -$172,513 |
| Employee Count | 423 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 2.41 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.26% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +11.26% |
| 50-Day Moving Average | 15.20 |
| 200-Day Moving Average | 17.38 |
| Relative Strength Index (RSI) | 56.81 |
| Average Volume (20 Days) | 1,440,259 |
Short Selling Information
The latest short interest is 6.61 million, so 14.69% of the outstanding shares have been sold short.
| Short Interest | 6.61M |
| Short Previous Month | 6.82M |
| Short % of Shares Out | 14.69% |
| Short % of Float | 33.22% |
| Short Ratio (days to cover) | 6.25 |
Income Statement
In the last 12 months, Beta Bionics had revenue of $119.01 million and -$72.97 million in losses. Loss per share was -$1.65.
| Revenue | 119.01M |
| Gross Profit | 69.40M |
| Operating Income | -83.02M |
| Pretax Income | -72.97M |
| Net Income | -72.97M |
| EBITDA | -80.80M |
| EBIT | -83.02M |
| Loss Per Share | -$1.65 |
Balance Sheet
The company has $180.49 million in cash and $6.51 million in debt, with a net cash position of $173.98 million or $3.87 per share.
| Cash & Cash Equivalents | 180.49M |
| Total Debt | 6.51M |
| Net Cash | 173.98M |
| Net Cash Per Share | $3.87 |
| Equity (Book Value) | 256.37M |
| Book Value Per Share | 5.70 |
| Working Capital | 205.02M |
Cash Flow
In the last 12 months, operating cash flow was -$55.81 million and capital expenditures -$5.60 million, giving a free cash flow of -$61.41 million.
| Operating Cash Flow | -55.81M |
| Capital Expenditures | -5.60M |
| Depreciation & Amortization | 2.22M |
| Net Borrowing | n/a |
| Free Cash Flow | -61.41M |
| FCF Per Share | -$1.37 |
Margins
Gross margin is 58.31%, with operating and profit margins of -69.75% and -61.32%.
| Gross Margin | 58.31% |
| Operating Margin | -69.75% |
| Pretax Margin | -61.32% |
| Profit Margin | -61.32% |
| EBITDA Margin | -67.89% |
| EBIT Margin | -69.75% |
| FCF Margin | n/a |
Dividends & Yields
Beta Bionics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -102.32% |
| Shareholder Yield | -102.32% |
| Earnings Yield | -9.89% |
| FCF Yield | -8.32% |
Analyst Forecast
The average price target for Beta Bionics is $20.08, which is 22.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $20.08 |
| Price Target Difference | 22.44% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 35.66% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Beta Bionics has an Altman Z-Score of 11.37 and a Piotroski F-Score of 2.
| Altman Z-Score | 11.37 |
| Piotroski F-Score | 2 |